Mutation or epigenetic silencing of mismatch repair genes, such as MLH1 and MSH2, results in microsatellite instability (MSI) in the genome of a subset of colorectal carcinomas (CRCs). However, little is yet known of genes that directly contribute to tumor formation in such cancers. To characterize MSI-dependent changes in gene expression, we have now compared transcriptomes between fresh CRC specimens positive or negative for MSI (n ¼ 10 for each) with the use of high-density oligonucleotide microarrays harboring >44 000 probe sets. Correspondence analysis of the expression patterns of isolated MSI-associated genes revealed that the transcriptome of MSI þ CRCs is clearly distinct from that of MSI À CRCs. Such MSI-associated genes included that for AXIN2, an important component of the WNT signaling pathway. AXIN2 was silenced, apparently as a result of extensive methylation of its promoter region, specifically in MSI þ CRC specimens. Forced expression of AXIN2, either by treatment with 5 0 -azacytidine or by transfection with AXIN2 cDNA, resulted in rapid cell death in an MSI þ CRC cell line. These data indicate that epigenetic silencing of AXIN2 is specifically associated with carcinogenesis in MSI þ CRCs.
Mutation or epigenetic silencing of mismatch repair genes, such as MLH1 and MSH2, results in microsatellite instability (MSI) in the genome of a subset of colorectal carcinomas (CRCs). However, little is yet known of genes that directly contribute to tumor formation in such cancers. To characterize MSI-dependent changes in gene expression, we have now compared transcriptomes between fresh CRC specimens positive or negative for MSI (n ¼ 10 for each) with the use of high-density oligonucleotide microarrays harboring >44 000 probe sets. Correspondence analysis of the expression patterns of isolated MSI-associated genes revealed that the transcriptome of MSI þ CRCs is clearly distinct from that of MSI À CRCs. Such MSI-associated genes included that for AXIN2, an important component of the WNT signaling pathway. AXIN2 was silenced, apparently as a result of extensive methylation of its promoter region, specifically in MSI þ CRC specimens. Forced expression of AXIN2, either by treatment with 5 0 -azacytidine or by transfection with AXIN2 cDNA, resulted in rapid cell death in an MSI þ CRC cell line. These data indicate that epigenetic silencing of AXIN2 is specifically associated with carcinogenesis in MSI þ CRCs. Oncogene (2006 Oncogene ( ) 25, 139-146. doi:10.1038 published online 10 October 2005 Keywords: epigenetics; colorectal carcinoma; microsatellite instability; AXIN2; MLH1 Colorectal carcinoma (CRC) is one of the leading causes of cancer death in humans. Evidence indicates the existence of two major types of genomic instability in CRCs: chromosomal instability and microsatellite instability (MSI) (Lengauer et al., 1998) . Whereas chromosomal instability is associated with an abnormal DNA content (such as aneuploidy), inactivation of the tumor suppressor gene TP53, and activation of oncogenes (Kinzler and Vogelstein, 1996) , MSI is associated with defects in DNA mismatch repair (MMR) that result in frameshift mutations in microsatellite repeats and thereby affect the structure of genes containing such repeats (Ionov et al., 1993) .
Although germline mutations of MMR genes have been detected in the genome of individuals with hereditary nonpolyposis colorectal cancer (Fishel et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994) , many sporadic CRCs positive for MSI are associated with epigenetic silencing of nonmutated MMR genes (Toyota et al., 1999; Miyakura et al., 2001) . MSI þ CRCs are characterized by specific clinicopathologic features and gene mutations. They occur with a higher frequency in women than in men, develop in the right side of the colon, and manifest a mucinous or poorly differentiated histopathology. Many of the CpG dinucleotides within the promoter region of the MMR gene MLH1 are methylated (Cunningham et al., 1998; Veigl et al., 1998) and the BRAF gene frequently contains activating mutations (Koinuma et al., 2004) 
CRCs. Multiple genomic fragments have been found to be methylated in such CRCs (Toyota et al., 1999) , and an entity of CRC with a CpG island methylator phenotype has been proposed (Issa, 2004) . The repertoire of genes that become methylated specifically in CRCs positive for MLH1 methylation has remained uncharacterized, however.
To characterize directly the transcriptome specifically associated with MSI þ CRC, we have now compared transcriptomes between fresh CRC specimens with or without MSI. Unexpectedly, we found that the expression of AXIN2, which encodes a component of the WNT signaling pathway, was markedly suppressed among the former tumors. CpG sequences within the AXIN2 promoter were revealed to be extensively methylated in such CRCs. Forced expression of AXIN2 inhibited cell proliferation in an MSI þ CRC cell line, indicating that loss of AXIN2 transcription is directly associated with carcinogenesis in MSI þ CRCs. To identify genes whose expression is specifically altered in MSI þ CRCs, we first compared the transcriptomes of CRCs with or without MSI. A total of 248 consecutive cases of CRC were examined for MSI status as well as for methylation of the promoter region of MLH1 (Koinuma et al., 2004) . Most (n ¼ 213) of the cancer specimens were MSI À , with the remainder (n ¼ 35) being positive for MSI. To compare the transcriptomes of these two subtypes of CRC, we randomly selected 10 specimens from each group and subjected them to gene expression profiling with microarrays (Affymetrix GeneChip HGU133) that harbor >44 000 probe sets. The clinical characteristics of the patients whose CRC specimens were subjected to microarray analysis are summarized in Table 1 .
To exclude transcriptionally silent genes from our analyses, we first chose probe sets that received the 'Present' call from Microarray Suite 5.0 (Affymetrix) in at least 10% (n ¼ 2) of the samples. Two-way hierarchical clustering (Alon et al., 1999) of the 20 patients based on the expression profiles of the isolated 21 888 probe sets failed to separate those with MSI þ CRC from those with MSI À CRC (data not shown). We therefore attempted to identify 'MSI-associated probe sets' whose expression intensities differed significantly (Student's t-test, Po0.001) between the two classes and whose effect size (absolute difference in mean expression level) was X50 U. Two-way clustering analysis with the 24 probe sets that fulfilled both these criteria clearly separated the individuals of the two clinical classes (Figure 1a) . The distinct transcriptomes of the two classes were also confirmed by correspondence analysis (Fellenberg et al., 2001) , which reduced the complexity of the gene expression patterns from 24 to three dimensions. Projection of the study subjects into a virtual threedimensional space based on their calculated coordinates revealed that the MSI þ specimens were positioned apart from the MSI À ones (Figure 1b ). These data indicate that the two classes of CRC possess distinct gene expression profiles, or 'molecular signatures', and they also suggest the feasibility of gene expression-based differential diagnosis of the two CRC subtypes. (a) Subject tree generated by two-way clustering analysis with 24 probe sets that contrasted the two clinical conditions (Po0.001; effect size, X50 U). Tumor samples were obtained from individuals with sporadic CRC who underwent surgical treatment at Jichi Medical School Hospital. Written informed consent was obtained from all patients, and the present study was approved by the ethics committee of Jichi Medical School. Microsatellite stability was determined by analysis of nine microsatellite repeat loci (three dinucleotide repeats and six mononucleotide repeats) as described previously (Miyakura et al., 2001) , and MSI status was stratified according to the criteria of the National Cancer Institute workshop (Boland et al., 1998) . Total RNA was extracted from B100 mg of tissue, and was used in the hybridization experiments with GeneChip HGU133 A&B microarrays (Affymetrix), which harbor >44 000 probe sets corresponding to B33 000 human genes, as described previously (Ohki-Kaneda et al., 2004) . The mean expression intensity of the internal positive control probe sets (http:// www.affymetrix.com/support/technical/mask_files.affx) on the microarrays was set to 500 units (U) in each hybridization, and the fluorescence intensity of each probe set was normalized accordingly. All normalized array data are available at the Gene Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo) under the Accession Number GSE2138. Each column corresponds to a separate sample (MSI À , green; MSI þ , red), and each row to a probe set whose expression is color-coded according to the indicated scale. Gene symbols are shown on the right; 225541_at, 226545_at, and 242414_at are expressed sequence tag IDs designated by Affymetrix (http:// www.affymetrix.com). Annotations and expression intensities for the probe sets are presented in Supplementary The isolated MSI-associated genes include AXIN2 and CTNNB1 (b-catenin), both of which encode key participants in the WNT signaling pathway (Tolwinski and Wieschaus, 2004) . Dysregulation of ubiquitindependent degradation of b-catenin contributes to carcinogenesis in a variety of CRCs and hepatocellular carcinomas (Narayan and Roy, 2003) . AXIN2, similar to AXIN1, functions as a scaffold protein to facilitate this ubiquitination process by recruiting adenomatous polyposis coli (APC), glycogen synthase kinase-3b, and b-catenin (Behrens et al., 1998) . Defects in the degradation of b-catenin have been shown to result from mutations in AXIN1, AXIN2, APC, or CTNNB1 (Rubinfeld et al., 1997; Liu et al., 2000; Satoh et al., 2000; Smith et al., 2002) . Our data therefore suggest that transcriptional suppression of AXIN2 might represent a novel mechanism by which the function of the APC-AXIN-b-catenin complex is impaired in CRC.
To confirm the MSI-associated change in AXIN2 expression, we measured the abundance of the corresponding mRNA in the original 20 study specimens by quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis (Figure 2a) . Comparison of the amount of AXIN2 mRNA determined by RT-PCR with that determined by microarray analysis yielded a Pearson's correlation coefficient (r) of 0.89, indicating that the two data sets were highly correlated (Po0.001). (Also see Supplementary Figure 1 for verification of microarray data by RT-PCR.) With the use of RT-PCR, we then measured the amount of AXIN2 mRNA in a larger number of samples (seven additional specimens of MSI þ CRC, for a total of 17; 10 additional specimens of MSI À CRC, for a total of 20; three MSI þ CRC cell lines; two MSI À CRC cell lines). The abundance of AXIN2 transcripts in most of the MSI þ CRC specimens and cell lines was reduced compared with that in the MSI À ones ( Figure 2b) ; an AXIN2/ACTB transcript ratio of o5 Â 10 À4 was apparent in 13 of the 17 MSI þ CRC specimens, but in only five of the 20 MSI À ones (Fisher's exact probability test, P ¼ 0.003). Importantly, a similar MSI-dependent suppression of AXIN1 expression was not observed among these specimens (P ¼ 0.31) (data not shown).
Human AXIN2 possesses a relatively large CpG island within its promoter region (nucleotide positions, chr17: 60986365-60987824). We therefore examined the methylation status of the CpG sites within this region by nucleotide sequencing after sodium bisulfite treatment. Extensive methylation of the CpG island in the AXIN2 promoter was apparent in CRC specimens positive for MSI and for the loss of AXIN2 expression (Figure 2c ). The promoter region in the MSI þ CRC cell line HCT116 (Wheeler et al., 1999) was also heavily methylated. The MLH1 promoter in HCT116 cells is not methylated, but the coding sequence of the gene contains a mutation that results in MSI (Wheeler et al., 1999) .
On the basis of these findings, we examined the methylation status of the AXIN2 promoter in 37 clinical specimens and five cell lines by combined bisulfite restriction analysis (COBRA) (Xiong and Laird, 1997) . CpG methylation was detected in five of the 17 MSI þ specimens, but in none of the 20 MSI À specimens (Table 1; see Supplementary Table 2 ). Methylation of the AXIN2 promoter was not detected in normal colon tissue obtained from the individuals with MSI þ CRC (data not shown), suggesting that AXIN2 methylation was a somatic event in these patients.
We then tested whether the amount of the encoded protein correlated with that of AXIN2 mRNA in CRC specimens (Figure 2d ). Immunohistochemical staining showed that AXIN2 was abundant in a specimen with a high mRNA content (ID308), but was present in much smaller amounts in two specimens with a low mRNA content (ID263, ID295). Although a large amount of AXIN2 mRNA was not always associated with a large amount of protein, a small amount of mRNA was consistently associated with a small amount of protein (data not shown).
To examine directly whether epigenetic silencing of AXIN2 is relevant to the change in the growth properties of CRC cells, we restored AXIN2 expression, either by 5 0 -azacytidine treatment or by introduction of AXIN2 cDNA, in an MSI þ CRC cell line. 5 0 -Azacytidine inhibits de novo methylation of genomic DNA and thereby induces demethylation of the genome of proliferating cells (Christman, 2002) . HCT116 cells were incubated for 3 days with various concentrations of 5 0 -azacytidine and were then subjected to COBRA for determination of the methylation status of the AXIN2 promoter. Treatment with 5 0 -azacytidine reduced the level of methylation of the AXIN2 promoter in a concentration-dependent manner (Figure 3a ). This effect of 5 0 -azacytidine was accompanied by an increase in the amount of AXIN2 mRNA in the cells (Figure 3b ) as well as by the induction of cell death (Figure 3c ).
Given that 5 0 -azacytidine likely affects the transcription of other genes in addition to that of AXIN2, the growth inhibitory effect observed in HCT116 cells might not have been attributable solely to the induction of AXIN2 expression. To examine the direct effect of AXIN2, we introduced its cDNA into HCT116 cells by transfection. However, an introduction of AXIN2 cDNA (even with the use of an inducible system) resulted in rapid cell death, and we could not establish stable transformants of cell lines with such expression constructs (data not shown). Therefore, we generated an amphotropic recombinant retrovirus that confers simultaneous expression of both an MYC epitope-tagged form of AXIN2 and mouse CD8. Human kidney 293 cells infected with this virus, but not those infected with a mock virus, expressed AXIN2 (Figure 3d) . HCT116 cells were then infected with the virus and were subjected to affinity chromatography 48 h thereafter to isolate cells that express CD8. Given that CD8-expressing cells would be expected also to express AXIN2, this column purification step should result in rapid enrichment of AXIN2-expressing cells. The isolated cells indeed contained a substantial amount of AXIN2 mRNA as revealed by RT-PCR (Figure 3e ). The purified CD8 þ HCT116 cells were then cultured for 3 days to characterize their growth properties. Forced expression of AXIN2 resulted in marked inhibition of cell growth (Figure 3f ), indicating that silencing of AXIN2 is indeed relevant to tumorigenesis. We also examined if the expression of AXIN2 directly suppresses the WNT signaling pathway. For this purpose, we utilized a luciferase-based reporter plasmid (TOPflash) for the T-cell factor (TCF) activity, which is a direct target of Immunohistochemical analysis of AXIN2 expression was performed as described previously (Leung et al., 2002) . Sections (5 mm) of formalin-fixed, paraffin-embedded tissue were mounted on Probe-On slides (Fisher Scientific), which were then incubated first for 1 h at room temperature with 1.5% normal horse serum and then overnight at 41C with goat polyclonal antibodies to AXIN2 (Santa Cruz Biotechnology). Immune complexes were detected by the avidin-biotin-peroxidase method with 3,3 0 -diaminobenzidine as the chromogenic substrate (Vectastain ABC kit, Vector Laboratories). The sections were counterstained with hematoxylin. Scale bar, 50 mm.
Epigenetic silencing of AXIN2 in colorectal cancer K Koinuma et al b-catenin (Korinek et al., 1997) . As shown in Figure 3g , a forced expression of AXIN2 induced a marked suppression in the luciferase activity in HCT116 cells. On the other hand, AXIN2 did not affect luciferase activity driven by a mutated, nonfunctional TCF-binding sites (FOPflash). These data clearly indicate that AXIN2 is involved in the WNT-APC-b-catenin pathway in CRCs.
We have demonstrated preferential transcriptional silencing of AXIN2 in MSI þ CRCs. Recently, mutations within exon 7 of the AXIN2 gene have been reported in MSI þ CRC specimens (Liu et al., 2000; Wu et al., 2001) . We have thus analysed the nucleotide sequence of the AXIN2 gene among our MSI þ samples (n ¼ 9). Sequencing of the AXIN2 exon 7 has revealed that only one patient (ID no. 263) carried a mutated AXIN2 gene in one allele (data not shown). A deletion of a cytosine residue at the nucleotide position 2096 of the AXIN2 cDNA (GenBank Accession Number, AF078165) led to a frame shift in the open-reading frame in this patient, introducing a premature termination codon in AXIN2 protein at the amino-acid position of 688. However, majority of the patients had intact AXIN2 genes, indicating that silencing, but not mutation, of AXIN2 is the main pathway to impede the AXIN2 function.
The COBRA experiments revealed that the promoter region of AXIN2 was extensively methylated in MSI þ CRCs but not in MSI À CRCs. Although the difference in the frequency of AXIN2 methylation between these two classes of tumor was significant (Fisher's exact probability test, P ¼ 0.003), the frequency for the MSI þ specimens was still only 29% and therefore was not able to account for all the observed instances of suppression of AXIN2 expression. We judged COBRA data as positive for methylation if X10% of the PCR products were digested by HhaI. However, a small proportion (o10%) of the PCR products was digested in the analysis of B50% of MSI þ CRC specimens (data not shown),
indicating that alterations in the methylation status of the AXIN2 promoter were more widespread. It is therefore possible that CpG sites other than that targeted by COBRA are more frequently methylated in MSI þ CRCs and are more important for transcriptional regulation.
Similar promoter methylation has been recently described for other genes important for the WNT signaling pathway. The genes for secreted frizzledrelated proteins are thus epigenetically silenced in MSI þ CRCs, resulting in constitutive activation of the WNT pathway (Suzuki et al., 2004) . CpG sites within the APC promoter were also found to be frequently methylated in CRCs and other cancers (Esteller et al., 2000; Zysman et al., 2002) . These data thus suggest that not only genetic mutations but also epigenetic silencing might play an important role in tumorigenesis mediated by activation of the WNT pathway.
Methylation of the APC promoter in endometrial cancer has been shown to occur preferentially in MSI þ tumors (Zysman et al., 2002) . Despite the lack of an MSI-associated difference in the expression of APC in our CRC specimens (data not shown), the results of this previous study together with our present findings suggest the possibility that genes related to the WNT signaling pathway are targeted for methylation specifically in cancers with MSI. Our data further indicate that such methylation in MSI þ cancers may be directly relevant to the mechanism of malignant transformation through epigenetic silencing of tumor suppressor genes. MSI þ CRCs have been thought to arise through genetic events distinct from those that underlie MSI À cancers (Rajagopalan and Lengauer, 2004) , which are frequently associated with aneuploidy and mutations in WNT pathway genes such as APC and CTNNB1. However, our data indicate that the molecular mechanisms for malignant transformation overlap between MSI þ and MSI À CRCs.
Figure 3 Induction of cell death by restoration of AXIN2 expression in a CRC cell line with a methylated AXIN2 promoter. (a) HCT116 cells were incubated for 72 h with 0, 0.2, or 1 mM 5 0 -azacytidine and were then subjected to COBRA for determination of the methylation status of the AXIN2 promoter (Xiong and Laird, 1997) . Genomic DNA was denatured, incubated for 16 h at 551C in 3.1 M sodium bisulfite, and then subjected to PCR with the primers in Figure 2c . The PCR products were then digested with the restriction endonuclease HhaI (Takara Bio), and the resulting DNA fragments were fractionated by polyacrylamide gel electrophoresis. The gel was stained with SYBR Green I (Takara Bio) and scanned with an LAS3000 imaging system (Fuji Film). Genomic fragments were determined to be positive for CpG methylation if X10% of the PCR products were cleaved by the restriction endonuclease. Lane M, DNA size markers (50-bp ladder). (b) The cells from (a) were also subjected to RT-PCR analysis for determination of the amount of AXIN2 mRNA relative to that of ACTB mRNA. (c) Cells treated as in (a) with 0, 0.2, 1, or 5 mM 5 0 -azacytidine were examined by light microscopy. Cell death was estimated by counting the remaining viable cells in each culture dish by the dye-exclusion method. Scale bar, 50 mm. (d) Human kidney 293 cells infected with either a mock virus or a recombinant virus encoding both MYC epitope-tagged AXIN2 and mouse CD8. A human cDNA for AXIN2 tagged at its NH 2 -terminus with the MYC epitope sequence was ligated into the pMX-iresCD8 retroviral plasmid (Yamashita et al., 2001) to yield pMX-AXIN2-MYC-iresCD8. The latter plasmid was introduced into BOSC23 cells together with pE-ampho and pGP packaging plasmids (Takara Bio) by transfection with the use of Lipofectamine (Invitrogen). The culture supernatant containing recombinant viruses was added to 293 cells with 4 mg/ml of polybrene (Sigma). Cells were then subjected to immunoprecipitation with the antibodies to MYC (9E10, Roche Diagnostics), and to immunoblot analysis with the same antibodies. (e) HCT116 cells infected with the viruses in (d) were subjected to affinity chromatography to isolate CD8 þ cells, which were then subjected to RT-PCR analysis for quantitation of AXIN2 mRNA relative to the amount of ACTB mRNA. (f) The CD8 þ fractions in (e) were seeded at a density of 5 Â 10 4 cells/dish and cultured for 72 h, after which the ratio of the final cell number to the initial value was determined. Data are means þ s.d. of triplicate from a representative experiment. The P-value for the indicated comparison was determined by Student's t test. (g) HCT116 cells were seeded at a density of 2.5 Â 10 6 cells/6 cm dish. After 24 h of incubation, the cells were transfected, with the use of Lipofectamine, with 2 mg of pMX-AXIN2-MYC-iresCD8 (AXIN2) or pMXiresCD8 (Mock). For the reporter plasmids, 0.5 mg of pGL4 (Promega, Madison, WI, USA) plus either 0.5 mg of pTOPflash or 0.5 mg of pFOPflash (both from Upstate Biotechnology, Lake Placid, NY, USA) were added to the lipofection mix. The activity of Photinus pyralis luciferase was measured after 24 h of incubation with the use of the Dual-luciferase reporter assay system (Promega), and normalized on the basis of the activity of Renilla reniformis luciferase produced by pGL4. Data are shown as the mean value þ s.d. of triplicate samples.
